Agency Forms Undergoing Paperwork Reduction Act Review

In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled “Focus on Advancing Support and Transition with the Fragile X Online Registry with Accessible Database (FAST FORWARD)” to the Office of Management and Budget (OMB) for review and approval. CDC previously published a “Proposed Data Collection Submitted for Public Comment and Recommendations” notice on April 28, 2026, to obtain comments from the public and affected agencies. CDC received two related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and

(e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639-7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/​public/​do/​PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide written comments within 30 days of notice publication.

Proposed Project

Focus on Advancing Support and Transition with the Fragile X Online Registry with Accessible Database (FAST FORWARD)—New—National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

Fragile X Syndrome (FXS) is a genetic disorder caused by changes in a gene called fragile X messenger ribonucleoprotein 1 (FMR1). FMR1 usually makes a protein called Fragile X Messenger Ribonucleoprotein (FMRP) that is needed for brain development. People with FXS make little or no FMRP. FXS is the most prevalent known cause of inherited intellectual disability and the most common monogenic cause of autism. Physical features of FXS include a narrow face with prominent jaw and forehead and large ears. Medical features can include dental crowning, otitis media, sinus infections, sleep disorder, and strabismus; developmental features can include intellectual disability, motor delays, poor eye contact, repetitive behaviors, seizure disorder, speech-language disorder, and symptoms of attention deficit hyperactivity disorder. FXS is typically diagnosed in early childhood when physical, medical, and developmental features are more recognized. It is estimated that one in 7,000 males and one in 11,000 females have FXS. ( printed page 68958)

The proposed data collection builds on and improves upon four previous CDC-funded data collection efforts focused on FXS. The first project (CDC-RFA-DD-07-003; 2008-2011) piloted an infrastructure to conduct data collection on people with FXS across multiple sites. The second project (CDC-RFA-DD-11-007; 2011-2015) developed and piloted the infrastructure for a registry and for longitudinal data collection. The third project (CDC-RFA-DD-15-003; 2015-2020) established the Fragile X Online Registry With Accessible Research Database (FORWARD), and the fourth project (CDC-RFA-DD-21-002; 2021-2026), which extended FORWARD to include Multiple Assessments for Research Characterization (FORWARD-MARCH) built on the foundation of the first two projects and continued data collection to conduct analyses to better characterize the natural history of FXS and meaningful outcome measures to improve the lives of people with FXS.

Congressional Language accompanying the 2026 Consolidated Appropriations Act funding for CDC's FXS activities encourages CDC to support additional strategies to promote earlier identification of children with FXS, to ensure populations with FXS conditions are being properly diagnosed and are made aware of available medical services, and support people with FXS and associated conditions and disorders across the lifespan.

This information collection request (ICR), consistent with Congressional intent, is developed to employ clinic-based enrollment of eligible participants aged 40 years old or younger with full mutation of FXS that attend clinics affiliated with the three U.S. sites funded for this project. Each participating clinic will recruit a minimum of 200 eligible persons with FXS for a total of 600 across all three sites. Information will be collected on diagnosis, co-occurring conditions and behaviors, communication, adaptive abilities, healthcare utilization and service needs, education, transition planning and experience, activities and social participation, future planning, caregiver supports, demographics, participant strengths, and other topics consistent with the goals of the project. Data will be collected through online caregiver surveys.

CDC requests OMB approval for an estimated 200 annual burden hours. There are no costs to respondents other than their time to participate.